Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Venous Thromboembolism Market from 2024 to 2025?

The size of the venous thromboembolism market has consistently expanded in the past few years. This market will see a progression from $2.44 billion in 2024 to $2.55 billion in 2025, with a compound annual growth rate (CAGR) of 4.4%. The factors influencing this growth augmentation during the historic period include the elderly population growth, improvements in anticoagulants, reimbursement policies, and an increase in investments.

What Is the Projected Market Size of the Venous Thromboembolism Market?

The market for venous thromboembolism is anticipated to experience consistent expansion in the coming years, reaching a value of $3.02 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.4%. This growth during the projected period is due to factors such as worldwide health care accessibility, genetic risk evaluation, telehealth, and remote patient monitoring, as well as patient education and support. The forecast period is also expected to witness trends like extended thromboprophylaxis, new oral anticoagulants, individualized treatment strategies, and advancements in diagnostic imaging.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp

Who are the Major Competitors in the Venous Thromboembolism Market Outlook?

Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

What Is Fueling Growth in the Venous Thromboembolism Market?

Predictions of accelerated growth in the venous thromboembolism market are interconnected with expanding healthcare infrastructure. The term healthcare industry encapsulates all sectors within the economic fabric that provide treatment, prevention, rehabilitation, and palliative care services to patients. Growth in this vast industry directly contributes to the growth of institutional infrastructure, policies, practices, and educational programs vital to the application of VTE prevention protocols. Data from the American Health Care Association shows the number of hospitals in the U.S jumped from 6,093 in 2022 to 6,129 in May 2023. Also, UK’s Office for National Statistics reported in May 2023, a nominal increase of 5.6% in the UK’s healthcare spend, which reached £292 billion. Further, there was a real increase of 2.8% in 2022 in long-term health and social care expenditure. Thus, the venous thromboembolism market is significantly bolstered by the growth of the healthcare industry. The venous thromboembolism market is further stimulated by the escalating number of orthopedic procedures. Orthopedic procedures, which include surgical treatments for spine and joint ailments and skeletal malformations, pose a high risk of VTE. This risk has boosted the use of compression devices for DVT prophylaxis to prevent blood clot formation in deep leg veins leading to venous thromboembolism. Research by the National Library of Medicine in February 2023 indicates an anticipated rise in total knee arthroplasty (TKA) and total hip arthroplasty (THA) procedures by 719,364 and 1,222,988 respectively by 2040. Projections also suggest an increase in TKAs to 2,917,959 and THAs to 1,982,099 by 2060. Consequently, these increasing figures in orthopedic procedures are propelling the growth of the venous thromboembolism market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13001&type=smp

Which Venous Thromboembolism Market Segments Are Growing the Fastest?

The venous thromboembolism market covered in this report is segmented –

1) By Type: Deep Vein Thrombosis, Pulmonary Embolism, Other Types

2) By Treatment: Anti-Clotting Medications,  Mechanical Devices, Thrombolytic Therapy, Other Treatment

3) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By Deep Vein Thrombosis (DVT): Proximal DVT, Distal DVT, Asymptomatic DVT

2) By Pulmonary Embolism (PE): Acute PE, Chronic PE, Submassive PE

3) By Other Types: Thrombophlebitis, Superficial Vein Thrombosis, Post-Thrombotic Syndrome

Which Industry Trends Are Shaping the Future of the Venous Thromboembolism Market?

Leading businesses in the venous thromboembolism market are focusing on the development of new anticoagulant medications and strategies to maintain their market stance. Emerging advancements in anticoagulants may result in more effective treatments for preventing or curing venous thromboembolism. As an example, Anthos Therapeutics, a clinical-stage biotherapeutics company located in the US, obtained clearance for its anticoagulant drug named abelacimab from the US government agency, the Food and Drug Administration (FDA), in September 2022. The approved drug is a fully human monoclonal antibody, designed for preventing stroke and systemic embolism in patients with atrial fibrillation. Abelacimab, a newly formulated once-monthly dual-acting antibody, is targeted at providing anticoagulation that spares hemostasis by inhibiting Factor XI.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Which Countries Are Leading the Venous Thromboembolism Market?

North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13001

This Report Delivers Insight On:

1. How big is the venous thromboembolism market, and how is it changing globally?

2. Who are the major companies in the venous thromboembolism market, and how are they performing?

3. What are the key opportunities and risks in the venous thromboembolism market right now?

4. Which products or customer segments are growing the most in the venous thromboembolism market?

5. What factors are helping or slowing down the growth of the venous thromboembolism market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model